As a result, researchers compared findings to adult patients with rheumatoid arthritis (RA). Admittedly, the study did not have a large number of patients with pJIA. The drug was found to be safe, effective, and well-tolerated. Despite using methotrexate, all 127 children still had active disease states. 127 children (2-17) with jPsA or pJIA enrolled. The FDA approved Simponi Aria using data from the Phase 3 GO-VIVA clinical trial. However, in time, this will progress to every 2 months. At first, patients are dosed every month. By blocking or inhibiting TNF-alpha, Simponi Aria reduces joint pain and inflammation. Tumor necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine. The therapy is an intravenously administered anti-TNF-alpha antibody. However, it now presents a more accessible treatment option for patients with pJIA and jPsA. Simponi AriaĬurrently, Simponi Aria is indicated for the treatment of adult patients with psoriatic arthritis, ankylosing spondylitis (AS), and moderate to severe rheumatoid arthritis. Prior to Simponi Aria, there were few treatments designed for patients with these subtypes. The therapy is designed to treat pediatric patients (ages 2 or older) with forms of juvenile arthritis: polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA). Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”) announced the FDA approval of Simponi Aria (golimumab).
0 kommentar(er)
